BDX vs NVCR
BDX: BD is a leading global medical technology company providing essential medical devices, diagnostic systems, and laboratory solutions to healthcare providers and researchers worldwide. NVCR: Novocure is an oncology company utilizing proprietary Tumor Treating Fields (TTFields) to disrupt cancer cell division through wearable, non-invasive electric field therapy.
Side-by-side fundamentals
| Metric | BDX | NVCR | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $152.97 | $19.99 | |
| Market cap as of 2026-07-26 | $43.1B | $2.0B | |
| P/E as of 2026-07-26 | 37.86 | n/a | |
| PEG as of 2026-07-26 | -20.92 | n/a | |
| Net margin as of 2026-07-26 | +5.3% | -25.7% | BDX higher |
| Gross margin as of 2026-07-26 | +47.0% | +75.4% | NVCR higher |
| Operating margin as of 2026-07-26 | +10.2% | -27.0% | BDX higher |
| ROE as of 2026-07-26 | +4.5% | -39.4% | BDX higher |
| ROA as of 2026-07-26 | +2.1% | -13.5% | BDX higher |
| Debt / equity as of 2026-07-26 | 0.72 | 0.59 | NVCR lower |
| Revenue growth (YoY) as of 2026-07-26 | +2.4% | +8.5% | NVCR higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | +6.8% | NVCR higher |
| Dividend yield as of 2026-07-26 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-26 | 0.20 | 1.00 | |
| 1-year return as of 2026-07-23 close | +8.3% | +40.7% | NVCR higher |
Fundamentals: Finnhub, as of 2026-07-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.